Lipids in Health and Disease · 2024 · 34 citations · 103 references
MedicinePharmacologyPharmacotherapyHepatic PharmacotherapyHepatologyMetabolismChronic Liver DiseaseHepatic MetabolismHepatic PathophysiologyLipid MetabolismLiver DiseaseMetabolic Liver DiseaseDisease Mechanism ElucidationHepatic Lipid AccumulationHepatic Lipid MetabolismHepatic Lipid StorageHepatic Triglyceride MetabolismLipid Metabolism DisturbancesMetabolic Disease Pathology
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world's population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders.
103
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo, Julia Kozlitina, Chao Xing et al. · Nature Genetics · 2008 · 3.4K citations · Full text
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine · 2022 · 3.2K citations · Full text
Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations